Skip to content
Toggle main navigation
International Society of Glomerular Disease logo
International Society of Glomerular Disease logo
      Log in
      Contact
      International Society of Glomerular Disease
      PO Box 60335, Florence, MA 01062 USA
      info@is-gd.org
      +16172862025
      Links
      • Not a member yet? Join ISGD
      Community engagement platform by Hivebrite.

      News

      Stay current with the latest news and media from ISGD.

      ISGD News Blog
      GN in Ten Podcast
      Filter by category
      All
      advocacy
      anca-associated vasculitis
      anti-nephrin autoantibodies
      APOL1
      awards
      basic and translational research
      clinical trials
      education
      events
      fellowship
      See all

      Results (31)

      Quantitative Proteomics: Recent Advances in Glomerular Disease and Nephrotic Syndrome

      Quantitative Proteomics: Recent Advances in Glomerular Disease and Nephrotic Syndrome

      AbstractBackground: Chronic kidney disease (CKD) affects nearly 10% (∼850 million people) of the global population and stands among leading causes of morbidity, mortality, and healthcare cost. Current clinical biomarkers including serum creatinine, estimated glomerular filtration rate (eGFR), and proteinuria, are all lagging indicators of nephron damage only after glomerular and podocyte injury an
      October 1, 2026
      Machine Learning as a Multifaceted Tool in Glomerular Diseases: Beyond Risk Prediction

      Machine Learning as a Multifaceted Tool in Glomerular Diseases: Beyond Risk Prediction

      AbstractBackground: Glomerular diseases are a heterogeneous group of disorders with highly variable clinical outcomes, ranging from spontaneous remission to progressive kidney failure. Traditional prognostic tools, including proteinuria, serum creatinine, and semiquantitative histopathologic scoring, capture only part of this complexity. In particular, they often reduce longitudinal patient data t
      October 1, 2026
      Cardiometabolic Risk, Evaluation, and Control in Lupus Nephritis

      Cardiometabolic Risk, Evaluation, and Control in Lupus Nephritis

      AbstractIntroduction: Lupus nephritis (LN) is associated with atherosclerotic cardiovascular disease but early recognition of cardiometabolic risk in patients with LN can facilitate risk optimization with disease-modifying strategies. To identify potential gaps in cardiometabolic risk management in LN in real-world practice, we aimed to evaluate the prevalence and trend in cardiometabolic risk, ev
      August 7, 2026
      Hypokalemic Distal Tubulopathy Secondary to Anti-Phospholipase A2 Receptor-Positive Membranous Nephropathy: An Exceptional Case

      Hypokalemic Distal Tubulopathy Secondary to Anti-Phospholipase A2 Receptor-Positive Membranous Nephropathy: An Exceptional Case

      AbstractIntroduction: Primary membranous nephropathy, one of the most common primary nephrotic syndromes in adults, rarely has tubular involvement. Two case reports have previously illustrated atypical tubular manifestations, including Liddle-like syndrome and proximal tubulopathy. Hypokalemic distal tubulopathy in anti-phospholipase A2 receptor antibody-positive membranous nephropathy has not yet
      July 9, 2026
      How Late Is Too Late? Successful Use of Targeted-Release Budesonide in IgA Nephropathy with Estimated Glomerular Filtration Rate <30 mL/min/1.73 m 2

      How Late Is Too Late? Successful Use of Targeted-Release Budesonide in IgA Nephropathy with Estimated Glomerular Filtration Rate <30 mL/min/1.73 m 2

      AbstractIntroduction: IgA nephropathy (IgAN) is a common cause of chronic kidney disease (CKD) worldwide. However, patients with advanced CKD and significant fibrosis on biopsy have limited treatment options, and clinical trials studying targeted-release budesonide have excluded individuals with low estimated glomerular filtration rate (eGFR). Case Presentation: We report a case of a 36-year-old m
      June 22, 2026
      Acute Care Visits and Subsequent Health-Related Quality of Life among Children and Adults with Glomerular Disease in the Cure Glomerulonephropathy Cohort

      Acute Care Visits and Subsequent Health-Related Quality of Life among Children and Adults with Glomerular Disease in the Cure Glomerulonephropathy Cohort

      AbstractIntroduction: Health-related quality of life (HRQOL) is an important patient-reported aspect of overall health and is understudied in patients with glomerular disease (GD). Conflicting data have emerged regarding whether acute care visits (ACVs) are associated with HRQOL. This report describes types of ACVs and their short-term impact on HRQOL in patients with minimal change disease (MCD),
      June 9, 2026
      Prognostic Value of Baseline and Early Proteinuria Changes in IgA Nephropathy: A US Cohort Study

      Prognostic Value of Baseline and Early Proteinuria Changes in IgA Nephropathy: A US Cohort Study

      AbstractIntroduction: Proteinuria is a key marker in IgA nephropathy (IgAN). However, long-term thresholds and significance of early changes in proteinuria remains unclear in US populations. Methods: Retrospective cohort study of 745 adult patients with IgA nephropathy from the TriNetX US network (2015–2023). The baseline Time-average proteinuria (TAP) were calculated and categorized as <500, 500–
      June 8, 2026
      Renal Histopathology and Outcomes of Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis: The Qatar Experience

      Renal Histopathology and Outcomes of Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis: The Qatar Experience

      AbstractIntroduction: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a severe small-vessel vasculitis with substantial morbidity. Data from the Gulf region are limited, restricting understanding of disease patterns and outcomes. This study describes the epidemiology, clinical features, kidney pathology, and management of ANCA-associated glomerulonephritis (ANCA-GN) in Qatar.
      June 5, 2026
      Transitions in Glomerular Disease

      Transitions in Glomerular Disease

      AbstractBackground: The transition from pediatric to adult care is a complex and challenging issue for increasing numbers of adolescents and young adults (AYA). Despite increasing attention to the transition of AYA with chronic medical conditions, there remain difficulties which vary by local resources, disease processes, and individual factors. There are also poorly understood factors regarding t
      June 1, 2026
      Glomerular Structure and Function in Type 2 Diabetes Stratified by Glomerular Basement Membrane Thickening

      Glomerular Structure and Function in Type 2 Diabetes Stratified by Glomerular Basement Membrane Thickening

      AbstractIntroduction: Glomerular structural-functional relationships in diabetes were tested, stratifying by glomerular basement membrane (GBM) thickness, an approach not previously explored. Methods: Research kidney biopsies were performed in 30 people with type 2 diabetes (T2D) and any of the following baseline characteristics: moderate/severe albuminuria (urine albumin:creatinine ratio [UACR]:
      May 28, 2026
      Interpretative Challenges of Variants of Uncertain Significance in Severe Treatment-Refractory Focal Segmental Glomerulosclerosis

      Interpretative Challenges of Variants of Uncertain Significance in Severe Treatment-Refractory Focal Segmental Glomerulosclerosis

      AbstractIntroduction: Steroid-resistant nephrotic syndrome (SRNS) frequently reflects an underlying monogenic podocytopathy; however, the increasing use of genomic testing has also led to frequent identification of variants of uncertain significance (VUS), complicating clinical interpretation and creating a risk of overattribution of causality. Case Presentations: We report a 22-year-old woman wit
      May 9, 2026
      An “All-in-One” Kidney Biopsy in AIDS: Crescentic Immune Complex-Mediated Glomerulonephritis, CD8-Driven Interstitial Nephritis, and Superimposed Thrombotic Microangiopathy

      An “All-in-One” Kidney Biopsy in AIDS: Crescentic Immune Complex-Mediated Glomerulonephritis, CD8-Driven Interstitial Nephritis, and Superimposed Thrombotic Microangiopathy

      AbstractIntroduction: Human immunodeficiency virus (HIV)-associated kidney disease encompasses a diverse spectrum of glomerular, tubulointerstitial, and vascular pathologies. While HIV-associated nephropathy and immune complex-mediated glomerular disease in the setting of HIV are well-recognized entities, their simultaneous presentation with thrombotic microangiopathy (TMA) and diffuse infiltrativ
      May 4, 2026
      Case Series of the Combination of Voclosporin and Belimumab Treatment of Lupus Nephritis

      Case Series of the Combination of Voclosporin and Belimumab Treatment of Lupus Nephritis

      AbstractIntroduction: Lupus nephritis (LN) remains challenging with high treatment failure and relapse rates. Current therapies often fail to achieve sustained renal remission. The objective of this research was to assess the safety and clinical effectiveness of dual therapy using voclosporin and belimumab in individuals with LN confirmed via kidney biopsy. Methods: Retrospective case series of 16
      April 30, 2026
      Clinical Remission as a Function of Exposure to Cyclophosphamide in Patients with Primary Membranous Nephropathy: A One-Year Cohort Study

      Clinical Remission as a Function of Exposure to Cyclophosphamide in Patients with Primary Membranous Nephropathy: A One-Year Cohort Study

      AbstractIntroduction: Primary membranous nephropathy (pMN) is a leading cause of nephrotic syndrome (NS) in adults. Cyclophosphamide (CYC) with glucocorticoids (GCs) is recommended for high and very high-risk patients, but the optimal treatment duration and cumulative dose remain unclear. This study aimed to compare the effectiveness and safety of short-duration (SD) versus long-duration (LD) oral
      April 7, 2026
      Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial Design

      Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial Design

      AbstractIntroduction: Nephrotic syndrome (NS) clinical trials often rely on biomarkers or clinical measures as primary endpoints, but these may not fully capture the treatment benefits that matter most to patients. Edema-related swelling, a central manifestation of NS, profoundly affects patients’ health-related quality of life, including physical function, severe physical and mental symptoms, and
      April 7, 2026
      Nudging Nephrologists in Cardiovascular Risk Assessment and Management in Glomerular Diseases Treated with Immunosuppressants: An Implementation Study

      Nudging Nephrologists in Cardiovascular Risk Assessment and Management in Glomerular Diseases Treated with Immunosuppressants: An Implementation Study

      AbstractIntroduction: Glomerulonephritis and its treatment may be associated with cardiometabolic disease, so optimizing glycaemic and lipid control is important to mitigate cardiovascular risk. We aimed to evaluate the impact of an electronic medical record (EMR)-based physician prompt on glycaemic and lipid management among older adults with glomerulonephritis receiving immunosuppressive therapy
      March 23, 2026
      Serum Phospholipase A2 Receptor Antibody Is Associated with Thrombogenesis in Primary Membranous Nephropathy: A Systematic Review and Meta-Analysis

      Serum Phospholipase A2 Receptor Antibody Is Associated with Thrombogenesis in Primary Membranous Nephropathy: A Systematic Review and Meta-Analysis

      AbstractIntroduction: Primary membranous nephropathy (PMN) is a leading cause of nephrotic syndrome in adults and is associated with an increased risk of thromboembolic events. The anti-serum phospholipase A2 receptor antibody (anti-PLA2R Ab) is highly specific for PMN, correlates with immunological disease activity, and evidence suggests that it may contribute to a prothrombotic state. This syste
      March 19, 2026
      Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits: An Immunologic Crossroads

      Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits: An Immunologic Crossroads

      AbstractBackground: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is largely regarded as a form of monoclonal gammopathy of renal significance; however, 70–80% of cases lack evidence of an associated monoclonal lymphoproliferative disorder. Emerging evidence suggests it is a shared clinicopathologic manifestation of multiple, distinct disease etiologies includin
      March 12, 2026
      Contactin-1-Associated Membranous Nephropathy after Multiple mRNA 1273 COVID-19 Vaccinations: A Case Report

      Contactin-1-Associated Membranous Nephropathy after Multiple mRNA 1273 COVID-19 Vaccinations: A Case Report

      AbstractContactin-1-associated membranous nephropathy is a rare type of membranous nephropathy typically seen in the setting of chronic inflammatory demyelinating polyneuropathy. Here we present a case of a 79-year-old man who presented with ankle edema and was found to have 2,888 milligrams of proteinuria per 24 h and membranous nephropathy on kidney biopsy. Staining for multiple membranous antig
      March 9, 2026
      Sodium-Glucose Cotransporter 2 Inhibitors in Lupus Nephritis and ANCA-Associated Vasculitis: Unmet Needs to be Addressed

      Sodium-Glucose Cotransporter 2 Inhibitors in Lupus Nephritis and ANCA-Associated Vasculitis: Unmet Needs to be Addressed

      AbstractBackground: Current treatment of severe autoimmune glomerulonephritis such as lupus nephritis (LN) and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) relies primarily on immunosuppression to reduce kidney inflammation and chronic damage. However, many patients exhibit persistent proteinuria despite treatment, which serves as a prognostic biomarker for long-term out
      March 3, 2026